Berth-Jones J, Damstra RJ, Golsch S Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003; 326:(7403)

Berth-Jones J. Topical treatments in the management of skin disease, 9th Edition. In: Griffiths C, Barker J, Bleiker T, Chalmers R, and Creamer D (eds). Oxford: Wiley-Blackwell; 2016

British Association of Dermatologists (BAD). NHSE consultation statement on bath emollients. 2018. (accessed March 2019)

Burden AD, Beck MH. Contact hypersensitivity to topical corticosteroids. British Journal of Dermatology. 1992; 127:(5)497-500

Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000; 142:(5)931-936

Cork MJ, Danby S. Skin barrier breakdown: a renaissance in emollient therapy. Br J Nurs. 2009; 18:(14)872-877

Cork MJ, Timmins J, Holden C An audit of adverse drug reactions to aqueous cream in children with atopic eczema. Pharmaceut J. 2003; 271:746-7

Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database of Systematic Reviews. 2015;

Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K, Cork MJ. The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. Br J Dermatol. 2011; 165:(2)329-334

DermNetNZ. Topical calcineurin inhibitors. 2008. (accessed 16 September 2020)

Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian Journal of Dermatology. 2014; 59:(5)

EMC. Piriton tablets. 2016. (accessed 16 September 2020)

Fini E, Schwartz S, Gao X. Steroid-Induced Ocular Hypertension/Glaucoma: Focus on Pharmacogenomics and Implications for Precision Medicine. Progress in Retinal and Eye Research. 2017; 56:(1)58-83

Francis NA, Ridd MJ, Thomas-Jones E A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment. 2016; 20:(19)1-84

Gong JQ, Lin L, Lin T Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006; 155:(4)680-687

Green C, Colquitt JL, Kirby J, Davidson P, Payne E. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess. 2004; 8:(47)iii-120

Grimalt R, Mengeaud V, Cambazard F The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007; 214:(1)61-67

Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006; 54:(1)1-18

Joint Formulary Committee. British National Formulary, Chapter 13-Skin. 2020. (accessed 16 September 2020)

Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004; 150:(6)1174-1181

Long CC, Finlay AY. The finger-tip unit--a new practical measure. Clin Exp Dermatol. 1991; 16:(6)444-447

Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019; 1:(1)

MHRA. Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients. 2018. (accessed 16 September 2020)

Moncrieff G, Cork M, Lawton S, Kokiet S, Daly C, Clark C. Use of emollients in dry-skin conditions: consensus statement. Clin Exp Dermatol. 2013; 38:(3)231-238

MRHA. Aqueous cream may cause skin irritation. 2014. (accessed 16 September 2020)

NICE. Eczema–atopic CKS. 2018.!prescribingInfoSub:19 (accessed 16 September 2020)

NICE. Atopic eczema in children under 12 years. 2007. (accessed 16 September 2020)

NICE. Tacrolimus and pimecrolimus for atopic eczema. 2004. (accessed 16 September 2020)

Palmer CN, Irvine AD, Terron-Kwiatkowski A Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006; 38:(4)441-446

Papier A, Strowd LC. Atopic dermatitis: a review of topical nonsteroid therapy. Drugs Context. 2018; 7

PCDS. Eczema Treatment Pathway. 2019. (accessed 16 September 2020)

Ponnambath N. How to reassure patients with topical steroid phobia. Prescriber. 2014; 25:(5)21-23

Public Health England. Antimicrobial resistance (AMR). 2019. (accessed 16 September 2020)

Santer M, Ridd M, Francis N Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. BMJ. 2018;

Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?. J Allergy Clin Immunol. 2014; 133:(6)1615-25.e1

Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?. J Allergy Clin Immunol. 2014; 133:(6)1615-25.e1

Williams HC. Established corticosteroid creams should be applied only once daily in patients with atopic eczema. BMJ. 2007; 334:(7606)

Williamson DA, Carter GP, Howden BP. Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns. Clin Microbiol Rev. 2017; 30:(3)827-860

Wirén K, Nohlgård C, Nyberg F Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2009; 23:(11)1267-1272

Dermatology prescribing update: eczema

02 November 2020
Volume 2 · Issue 11


Eczema is a common skin condition, which for the majority is managed in primary care. Nurse prescribers should be aware of evidence–based guidelines in eczema treatment, on which they need to base prescribing decisions and work with the patient on individual skin care plans. Education and support in managing eczema is essential for patients of all ages (and carers of children and older people). Eczema has a huge impact on quality of life but a good management plan can make a big difference to controlling eczema, which is a chronic condition. This article explains the principles of eczema treatments, in acute, sub-acute and chronic stages of eczema with emollients, topical corticosteroids, antibiotics, antimicrobials and antivirals, topical calcineurin inhibitors and antihistamines.

This article will examine the guidance and evidence for prescribing topical treatments in eczema management. Prescribers will assess patients with eczema and should manage symptoms according to national guidance. NICE provides clinical knowledge summaries and specific guidance for children with atopic eczema under 12 years of age (National Institute of Health and Care Excellence (NICE), 2007; 2018). The Primary Care Dermatology Society (PCDS) provides eczema treatment pathways with practical advice for managing adults and children with eczema in primary care (PCDS, 2019). An overview of the PCDS eczema treatment pathways are outlined in Box 1. This article will explore the benefits and risks of the five main topical treatment strategies for eczema: emollients, topical corticosteroids, topical immunomodulators, antimicrobials and antihistamines.

Box 1.Management ABC

Source: NICE, 2007

Emollients are first-line therapy in eczema, this is evidence-based UK guidance (NICE 2007; 2018; PCDS, 2019). Complete emollient therapy should always be advised, this is: ‘everything that goes on the skin should be emollient-based, and all soaps and detergents should be replaced with emollient wash, bath and shower products (NICE, 2007; Cork and Danby, 2009). Most emollients can be used as soap substitutes and eave-on emollients.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month